MK-0752   Click here for help

GtoPdb Ligand ID: 11360

Synonyms: MK0752
Compound class: Synthetic organic
Comment: MK-0752 is a γ-secretase [1] and Notch pathway inhibitor that was originally intended for the treatment of Alzheimer's disease, but was later redeployed for anti-tumour potential.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 79.82
Molecular weight 442.08
XLogP 5.14
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(=O)CCC1CCC(CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(cc1)Cl
Isomeric SMILES OC(=O)CCC1CCC(CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(cc1)Cl
InChI InChI=1S/C21H21ClF2O4S/c22-15-2-5-17(6-3-15)29(27,28)21(18-13-16(23)4-7-19(18)24)11-9-14(10-12-21)1-8-20(25)26/h2-7,13-14H,1,8-12H2,(H,25,26)
InChI Key XCGJIFAKUZNNOR-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
MK-0752 progressed to early stage clinical evaluation in a number of cancer types, but as of January 2021 there were no active trials on ClinicalTrials.gov.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00572182 MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer Phase 1 Interventional Pediatric Brain Tumor Consortium Merck discontinued support for this study, so further accrual of participants was permanently stopped in 2011. 3
NCT00100152 A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) Phase 1 Interventional Merck Sharp & Dohme Corp.
NCT01098344 MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery Phase 1 Interventional Cancer Research UK 2